Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous natural killer cell-like cytotoxic T-lymphocytes + alpha-type-1 polarized dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intraperitoneal, Intradermal
01
Overview
Autologous natural killer cell-like cytotoxic T-lymphocytes (nCTLs) combined with an alpha-type-1 polarized dendritic cell (alphaDC1) vaccine is an experimental immunotherapy regimen developed by Roswell Park Comprehensive Cancer Center for the treatment of advanced gynecologic malignancies, including ovarian, fallopian tube, and primary peritoneal cancers. The nCTLs are patient-derived T cells that are laboratory-conditioned to express NK-like receptors and cytotoxic functions, allowing them to target tumor cells more effectively. These cells are delivered directly into the peritoneal cavity to target local disease. The alphaDC1 vaccine is a specialized dendritic cell formulation that promotes a Th1-polarized immune environment, enhancing the survival, expansion, and anti-tumor efficacy of the co-administered nCTLs.
- Other names
- Autologous natural killer cell-like CTLsAlpha-type-1 polarized dendritic cell vaccineAlpha-type1 polarized dendritic cell vaccineAlpha-type 1 polarized dendritic cell vaccinenCTLs and alphaDC1 vaccine
02
Targets
DLK1 (Delta-like homolog 1)MICB (Major histocompatibility complex class i-related protein B)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on autologous natural killer cell-like cytotoxic T-lymphocytes + alpha-type-1 polarized dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous natural killer cell-like cytotoxic T-lymphocytes + alpha-type-1 polarized dendritic cell vaccine.